Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Buy” by Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $20.83.

Several analysts have recently commented on ZVRA shares. Canaccord Genuity Group lowered their price target on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, September 18th. Guggenheim initiated coverage on Zevra Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $20.00 target price on the stock. Maxim Group raised their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Roth Mkm boosted their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th.

Hedge Funds Weigh In On Zevra Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in Zevra Therapeutics in the fourth quarter valued at approximately $177,000. Mystic Asset Management Inc. grew its stake in shares of Zevra Therapeutics by 15.4% during the 1st quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock valued at $1,545,000 after buying an additional 35,514 shares during the period. Retirement Planning Co of New England Inc. increased its holdings in shares of Zevra Therapeutics by 11.0% during the 1st quarter. Retirement Planning Co of New England Inc. now owns 430,193 shares of the company’s stock worth $2,495,000 after buying an additional 42,766 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Zevra Therapeutics by 3.6% in the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after buying an additional 58,866 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new position in Zevra Therapeutics in the first quarter valued at $64,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Stock Up 0.8 %

ZVRA opened at $8.53 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. The company has a market cap of $357.01 million, a price-to-earnings ratio of -6.32 and a beta of 1.94. Zevra Therapeutics has a one year low of $3.89 and a one year high of $8.95. The business’s fifty day moving average is $7.50 and its two-hundred day moving average is $5.94.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The business had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. During the same quarter in the prior year, the firm earned ($0.15) earnings per share. Analysts anticipate that Zevra Therapeutics will post -1.63 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.